Pulsed ElectroMagnetic Field Therapy With Square Wave Forms and Artificial Intelligence Within the Software Interface for Individualised, Bespoke Bio-Electromagnetic Therapy to Treat Symptoms of Chronic Lyme Disease Remaining After Antibiotics Treatment
Phase: NA
Conditions: Lyme Disease, Lyme Neuroborreliosis, Lyme Arthritis, Unknown Origin Fever
Sponsor: Kasey Phifer

The National Centre for Electro-Magnetic Therapies CIC 
 
Identifiers: NCT04577053   Unique Protocol ID: PEMF-BRI-Lyme-Disease-2020   Secondary 
IDs: Bioresonance Biofeedback 
Brief Title: PEMF Therapy to Treat Lingering Symptoms of Lyme Disease After Treatment 
With Antibiotics 
 
Date: Thursday 2nd September 2021 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

What is Lyme Disease?  
 
Lyme Disease is a bacterial infection transmitted from ticks to humans. This disease is often common 
in humans who live in wooded or grassy areas (such as North England and the Scottish Highlands) 
and are unprotected when outdoors. Whilst there are precautions for areas with higher populations 
of ticks, it is still possible to contract Lyme Disease anywhere in the UK. It is important to note that 
not all ticks will carry Lyme Disease, but that you should safely remove ticks as soon as possible. 
 
 
Symptoms of Lyme Disease 
 
A bite from a normal tick may cause itching, a rash, or a raised surface on the skin for a few days, 
with symptoms subsiding quickly. Lyme Disease, however, has both short and long-term symptoms, 
and can arise within 1 to 4 weeks, or can emerge up to 3 months after being bitten.  
Symptoms usually start with a rash that may look like a bullseye on the skin, with darker colouration 
closer to the centre of the bite.  
 
Short Term Symptoms:  
1. Fever or Chills 
2. Headaches 
3. Joint or Muscle Pain 
4. Tiredness or Loss of Energy 
5. Swollen Lymph Nodes 
 
Whilst the short-term symptoms may seem easily rectified, Lyme Disease can pose a serious threat 
to an individual in the long term. The longer a patient goes without treatment, the higher the risk of 
such symptoms occurring.  
All the potential symptoms of long-term Lyme Disease are listed below:  
1. Rashes across the body  
2. Bouts of severe joint pain and swelling, especially in the knees 
3. Neurological issues – Inflammation of the brain (Meningitis), Paralysis of the face (Bell’s 
Palsy), Numbness or Weakness in Limbs, impaired muscle movement, and Neuropathy.  
4. Heart Problems 
5. Eye Inflammation 
6. Liver Inflammation (Hepatitis)  
7. Severe Fatigue (Fibromyalgia)  
8. Severe Headaches and Neck Stiffness 
9. Inflammation of Brain and Spinal Cord 
10. Nerve Pain and Shooting Pain across the body  

11. Issues with Memory and Concentration  
12. Episodes of Dizziness and Shortness of Breath 
 
There is treatment for Lyme Disease from the NHS. You will be referred to a GP and given a blood 
test. The NHS specify that these blood tests can be inaccurate initially, so you may be required to 
retake them to confirm the presence of Lyme Disease in your system. If diagnosed, a GP will 
prescribe a course of anti-biotics for at least 28 days, where symptoms should improve. If symptoms 
are more severe, a patient may be redirected into hospital for direct anti-biotic treatment, or to see 
a specialist for alternative medication and supervision.  
 
NCET Clinical Trial on Lyme Disease  
 
The National Centre for Electromagnetic Therapies (formally Biofeedback Centre Bristol) undertook 
a clinical trial in October to December 2020 that sought to ease the symptoms for Lyme Disease 
patients. The trial and therapy was focussed on Pulsed Electromagnetic Therapy (PEMF) in treating 
the disease and followed weekly sessions with volunteers.  
In this study 10 patients were chosen to undergo PEMF treatment. These were 60-minute sessions 
where a patient was hooked up to SCIO devices, which scan and treat the body for an array of 
symptoms related to Lyme Disease. These sessions lasted 8 weeks at NCET’s Weston-Super-Mare 
Clinic, with surveys completed at different time increments. The clinical trial had an equal mixture of 
men and women over the age of 18.  
 
Initial Survey Before Trial  
 
Before the trial took place, volunteers were asked to fill out a survey relating to specific symptoms.  
These included fatigue, joint pain, and mood. It would then be compared with later results after 
treatment. Patients would respond to statements about their health by rating their experiences out 
of 100. 100 would indicate no issue whatsoever, whilst 0 indicated a very severe experience with the 
specific symptom. Their score would help us define whether specific symptoms were Severe, 
Moderate, or None.  
Here are the initial ratings of all participants prior to the clinical trial:  
 
1. Myalgia 
• 
50% --> Severe 
• 
40% --> None 
• 
10% --> Moderate 
2. Anxiety, Nerve Tension & Stress 
• 
80% --> Severe 
• 
20% --> Moderate 
• 
0% --> None 

3. Joint Aches 
• 
70% --> Severe 
• 
30% --> None 
• 
0% --> Moderate 
4. Fatigue 
• 
90% --> Severe 
• 
10% --> Moderate 
• 
0% --> None 
5. Depression 
• 
60% --> Severe 
• 
30% --> None 
• 
10% --> Moderate 
6. Brain Fog 
• 
80% --> Severe 
• 
0% --> Moderate 
• 
20% --> None 
7. Air Hunger 
• 
60% --> Severe 
• 
40% --> None 
• 
0% --> Moderate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Results  
 
Over the course of the clinical trial, there were improvements for all volunteers. This showed a great 
promise for using PEMF therapy in treating symptoms of Lyme Disease. In contrast to their initial 
surveys, many patients moved from being in the ‘Severe’ category into the ‘Moderate’ or ‘None’ 
categories. Sub-categories of symptoms were created to measure the success of the treatment, with 
percentages indicating an improvement from their initial survey. Results are as follows:  
1. Myalgia 
• 
18,33% --> Severe 
• 
16,67% --> Moderate  
• 
N/A --> None.  
2. Anxiety, Nerve Tension and Stress 
• 
26.3% --> Severe 
• 
25% --> Moderate 
• 
N/A --> None (no participants in group) 
3. Joint Aches 
• 
24,31% --> Severe 
• 
N/A --> Moderate (no participants in group) 
• 
N/A --> None. Participates identified as having hardly any or no joint aches and 
pains. Should participants in that segment suddenly develop joint pain within 2 
months, this is unrelated to the intervention being researched. 
4. Fatigue 
• 
16,4% --> Severe 
• 
33,33% --> Moderate (one participant only) 
• 
N/A --> None 
5. Depression 
• 
29,63% --> Severe 
• 
28,57% --> Moderate (one participant only) 
• 
-9,26% --> None** This signifies a decline, not improvement 
6. Brain Fog 
• 
23,46% --> Severe 
• 
N/A --> Moderate (no participants in group) 
• 
5,00% --> None 
7. Air Hunger 
• 
47,08% --> Severe 
• 
N/A --> Moderate (no participants in group) 
• 
3,75% --> None 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion and Conclusion 
 
The clinical trial provided promising results regarding the efficacy of Pulsed Electro-Magnetic 
Therapy in treating symptoms of Lyme disease. Firstly, there was the most improvement across all 
symptoms for participants in the ‘Severe’ categories. This indicates that PEMF therapy is especially 
useful in lowering extreme symptoms of Lyme Disease to a more moderate category. PEMF therapy 
was also shown to be most effective in treating Air Hunger and Depression symptoms. This reveals 
that SCIO devices may encourage cell regeneration in the lungs and brain more-so than other 
locations in the body during initial therapy.  
The trial also gave positive results for participants suffering with ‘Moderate’ symptoms. Whilst the 
rate of improvement was not as high overall as the ‘Severe’ category, PEMF therapy was shown to 

lower the severity of Depression and Fatigue in participants at a higher rate than those suffering 
with the same symptoms in the ‘Severe’ category.  
It is important to note that a few of the results were restricted by the number of participants in each 
category. For Fatigue and Depression in the ‘Moderate’ category, there was only one participant. 
This indicates that the results may not be representative of a larger study group, and therefore 
should be treated with caution when assessing the efficacy of PEMF therapy. Another participant, 
who defined themselves as having little to no symptoms of Depression, experienced more moderate 
symptoms as the trial went on. It is difficult to speculate whether this increase in severity was due to 
the clinical trial or was due to personal experiences outside of the treatment. If a participant was to 
indicate that their symptoms worsened severely, they were recommended to stop the trial and seek 
professional medical help. This did not occur during the clinical trial.  
As PEMF therapy encourages the relaxation of the mind, it is prudent to suggest that this participant 
was experiencing difficulties outside of the clinical trial (through personal relationships, national 
lockdowns, or other factors), which impacted their ratings in the concluding survey. Nonetheless it 
remains a topic to be considered during future clinical trials, to determine whether PEMF therapy 
can induce negative effects on participants suffering from depression.  
NCET have been limited in their research of the effects of PEMF therapy and Lyme Disease. Although 
initial results were positive, follow-ups with the patients after the trial became difficult. Therefore, it 
is difficult to draw reliable conclusions of the long-term benefits of PEMF therapy, and the effects of 
discontinuing therapy after the clinical trial. It became clear that the emergence of a third national 
lockdown, and general COVID-19 society had impacted the lives of many and may have reverted 
some patients back towards more severe symptoms due to lack of social mobility, financial issues, or 
other related problems. As fewer than 50% of participants filled out a survey after 6 months 
following the trial, it was decided to not to use such results as a reliable conclusion.  
The benefits of PEMF therapy in immediately treating Lyme Disease are more conclusive. This trial 
reveals that a short period of PEMF therapy promotes healing of all listed categories. Whilst the 
improvements are below 50%, it is important to note that this clinical trial was conducted over a 
short period of time with limited participants. Should PEMF therapy have continued with patients 
over a longer trial period, it is safe to assume that symptoms would continue to improve, even 
subside completely. NCET are confident in concluding that Pulsed Electro-Magnetic Therapy, 
conducted in weekly hour-long sessions, can improve the long-term symptoms of Lyme Disease in a 
non-invasive, affordable manner, although continued use of such therapies is recommended.  
A clinical trial researching the benefits of PEMF therapy on PTSD and Anxiety is soon to be conducted 
by NCET. This is in direct response to concerns surrounding depression improvements during the 
Lyme Disease clinical trial. This study will be published through Clinical Trials when completed.  
Further information regarding NCET’s services, clinics, and research are available through the 
website www.ncet.co.uk.